Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025 Report Highlights:
In clinical practice, CD70 targeting therapies are demonstrating considerable potential in treating hematological malignancies, particularly acute myeloid leukemia (AML), as well as solid tumors like renal cell carcinoma (RCC). AML is particularly challenging to manage with standard therapies, especially in patients who are unsuitable for intensive chemotherapy. Clinical trials focused on CD70 targeted therapies have shown promise in addressing this issue, with monoclonal antibodies and engineered cell therapies offering new hope for patients with few treatment options. The most advanced CD70-targeting therapy currently in clinical development is Cusatuzumab, created by argenx, which is presently undergoing Phase 2 trials in conjunction with chemotherapeutic agents for AML patients. This combination strategy seeks to enhance the effectiveness of Cusatuzumab by tackling resistance mechanisms and improving overall patient outcomes.
The application of CD70 targeting therapies extends beyond cancer treatment. These therapies are also being investigated for autoimmune diseases, viral infections, and graft-versus-host disease (GvHD), although they remain in the early stages of research. In these contexts, where immune responses are dysfunctional, CD70 targeting agents hold the potential to modulate the immune system and restore normal immune function. The expansion of therapeutic applications significantly fuels interest in this sector, as it broadens the potential market for these treatments.
In commercial terms, the US stands as hub for CD70 targeting therapy research and development. A robust ecosystem comprising biotechnology companies, pharmaceutical enterprises, and research institutions has driven the advancement of these therapies. Notable institutions such as Baylor College of Medicine, the National Institutes of Health, and cancer centers like City of Hope are conducting crucial clinical trials. Furthermore, regulatory support from the US FDA, including the Fast Track Designation for Adicet Bio’s ADI-270 and the Regenerative Medicine Advanced Therapy designation for Allogene Therapeutics’ ALLO-316, has expedited the development and commercialization processes. This regulatory endorsement is vital in facilitating access to new treatments, positioning the US as the heart for both clinical development and market introduction.
China is emerging as a significant contender in the global CD70 targeting therapy landscape. The country's rapidly growing biotechnology sector, bolstered by increased investments and partnerships with international companies, has enabled swift advancements in innovative therapies. Chinese research institutions are increasingly involved in clinical trials, while local biotech firms are progressing towards the commercialization of CD70 targeting therapies.
The intensifying competition within the CD70 targeting therapy market is fostering innovation, with several companies, including Allogene Therapeutics, Seagen (Pfizer), and CRISPR Therapeutics, developing novel treatments. These organizations are engaged in comprehensive preclinical and clinical research to assess the safety and efficacy of their therapies, thereby enhancing the therapeutic potential of CD70 targeted interventions. As more therapies enter clinical trials and yield favorable outcomes, the commercial opportunities for CD70 targeting therapies are expanding.
In conclusion, the integration of favorable clinical results and a dynamic commercial landscape establishes CD70 targeting therapies as a crucial component of the future of precision medicine. As an increasing number of companies and research organizations dedicate resources to these therapies, their capacity to tackle a diverse array of diseases expands, indicating the prospect of both clinical and commercial achievements ahead.
Global CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025 Report Highlights:
- CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
- CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication and Phase
- Insight On CD70 Targeting Therapy Technology Platforms
- FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
- Global & Regional Market Development Insight
- Combination Strategies For CD70 Targeting Therapies
In clinical practice, CD70 targeting therapies are demonstrating considerable potential in treating hematological malignancies, particularly acute myeloid leukemia (AML), as well as solid tumors like renal cell carcinoma (RCC). AML is particularly challenging to manage with standard therapies, especially in patients who are unsuitable for intensive chemotherapy. Clinical trials focused on CD70 targeted therapies have shown promise in addressing this issue, with monoclonal antibodies and engineered cell therapies offering new hope for patients with few treatment options. The most advanced CD70-targeting therapy currently in clinical development is Cusatuzumab, created by argenx, which is presently undergoing Phase 2 trials in conjunction with chemotherapeutic agents for AML patients. This combination strategy seeks to enhance the effectiveness of Cusatuzumab by tackling resistance mechanisms and improving overall patient outcomes.
The application of CD70 targeting therapies extends beyond cancer treatment. These therapies are also being investigated for autoimmune diseases, viral infections, and graft-versus-host disease (GvHD), although they remain in the early stages of research. In these contexts, where immune responses are dysfunctional, CD70 targeting agents hold the potential to modulate the immune system and restore normal immune function. The expansion of therapeutic applications significantly fuels interest in this sector, as it broadens the potential market for these treatments.
In commercial terms, the US stands as hub for CD70 targeting therapy research and development. A robust ecosystem comprising biotechnology companies, pharmaceutical enterprises, and research institutions has driven the advancement of these therapies. Notable institutions such as Baylor College of Medicine, the National Institutes of Health, and cancer centers like City of Hope are conducting crucial clinical trials. Furthermore, regulatory support from the US FDA, including the Fast Track Designation for Adicet Bio’s ADI-270 and the Regenerative Medicine Advanced Therapy designation for Allogene Therapeutics’ ALLO-316, has expedited the development and commercialization processes. This regulatory endorsement is vital in facilitating access to new treatments, positioning the US as the heart for both clinical development and market introduction.
China is emerging as a significant contender in the global CD70 targeting therapy landscape. The country's rapidly growing biotechnology sector, bolstered by increased investments and partnerships with international companies, has enabled swift advancements in innovative therapies. Chinese research institutions are increasingly involved in clinical trials, while local biotech firms are progressing towards the commercialization of CD70 targeting therapies.
The intensifying competition within the CD70 targeting therapy market is fostering innovation, with several companies, including Allogene Therapeutics, Seagen (Pfizer), and CRISPR Therapeutics, developing novel treatments. These organizations are engaged in comprehensive preclinical and clinical research to assess the safety and efficacy of their therapies, thereby enhancing the therapeutic potential of CD70 targeted interventions. As more therapies enter clinical trials and yield favorable outcomes, the commercial opportunities for CD70 targeting therapies are expanding.
In conclusion, the integration of favorable clinical results and a dynamic commercial landscape establishes CD70 targeting therapies as a crucial component of the future of precision medicine. As an increasing number of companies and research organizations dedicate resources to these therapies, their capacity to tackle a diverse array of diseases expands, indicating the prospect of both clinical and commercial achievements ahead.
1. INTRODUCTION TO CD70 TARGETING THERAPY
1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic & Prognostic Biomarker
2. CD70 TARGETING THERAPEUTIC APPROACHES
2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy
3. CD70 TARGETING THERAPIES CLINICAL RESEARCH & DEVELOPMENT BY INDICATIONS
3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune & Inflammatory Disease
3.7 Viral Infections
4. GLOBAL CD70 TARGETING THERAPIES CLINICAL TRIALS OVERVIEW
4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment
5. CD70 TARGETING THERAPIES REGULATORY DESIGNATIONS: FAST TRACK & ORPHAN DESIGNATION
6. GLOBAL CD70 TARGETING THERAPIES CLINICAL TRIALS INSIGHT
6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II
7. CD70 TARGETING THERAPIES DEVELOPMENT PLATFORMS BY COMPANY & TECHNOLOGY
7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing
8. GLOBAL CD70 TARGETING THERAPIES CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Forecast
9. CD70 TARGETING THERAPIES MARKET OPPORTUNITY & CLINICAL TRENDS BY REGION
9.1 US
9.2 China
9.3 Europe
10. COMBINATION STRATEGIES FOR CD70 TARGETING THERAPIES
10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy
11. GLOBAL CD70 TARGETING THERAPIES MARKET DYNAMICS
11.1 Market Drivers
11.2 Market Challenges
12. COMPETITIVE LANDSCAPE
12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson & Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics
Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History & Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 2-1: Approaches For Targeting CD70
Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners – MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study – Initiation & Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study – Initiation & Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study – Initiation & Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study – Initiation & Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study – Initiation & Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study – Initiation & Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study – Initiation & Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study – Initiation & Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study – Initiation & Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study – Initiation & Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 4-1: Global – CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global – CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global – CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global – CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global – CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global – CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025
Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR ?? T Cell Therapy
Figure 7-4: Catamaran Bio – Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta – CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 8-1: CD70 Targeting Therapy Current Market – Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market – Challenges
Table 6-1: CD70 Targeting Therapies With Regulatory Designations
1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic & Prognostic Biomarker
2. CD70 TARGETING THERAPEUTIC APPROACHES
2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy
3. CD70 TARGETING THERAPIES CLINICAL RESEARCH & DEVELOPMENT BY INDICATIONS
3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune & Inflammatory Disease
3.7 Viral Infections
4. GLOBAL CD70 TARGETING THERAPIES CLINICAL TRIALS OVERVIEW
4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment
5. CD70 TARGETING THERAPIES REGULATORY DESIGNATIONS: FAST TRACK & ORPHAN DESIGNATION
6. GLOBAL CD70 TARGETING THERAPIES CLINICAL TRIALS INSIGHT
6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II
7. CD70 TARGETING THERAPIES DEVELOPMENT PLATFORMS BY COMPANY & TECHNOLOGY
7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing
8. GLOBAL CD70 TARGETING THERAPIES CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Forecast
9. CD70 TARGETING THERAPIES MARKET OPPORTUNITY & CLINICAL TRENDS BY REGION
9.1 US
9.2 China
9.3 Europe
10. COMBINATION STRATEGIES FOR CD70 TARGETING THERAPIES
10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy
11. GLOBAL CD70 TARGETING THERAPIES MARKET DYNAMICS
11.1 Market Drivers
11.2 Market Challenges
12. COMPETITIVE LANDSCAPE
12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson & Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics
Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History & Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 2-1: Approaches For Targeting CD70
Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners – MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study – Initiation & Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study – Initiation & Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study – Initiation & Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study – Initiation & Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study – Initiation & Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study – Initiation & Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study – Initiation & Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study – Initiation & Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study – Initiation & Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study – Initiation & Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 4-1: Global – CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global – CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global – CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global – CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global – CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global – CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025
Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR ?? T Cell Therapy
Figure 7-4: Catamaran Bio – Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta – CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 8-1: CD70 Targeting Therapy Current Market – Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market – Challenges
Table 6-1: CD70 Targeting Therapies With Regulatory Designations
